Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCR-ABL peptide vaccine for CML minimal residual disease
NCT00428077Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Oct 2005
- Primary completion
- Apr 2009
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CMLVAX100 in Chronic Myeloid Leukemia (CML), sponsored by OHSU Knight Cancer Institute. Started Oct 2005; status: terminated.
02
Drugs
CMLVAX100
03
Conditions
Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT00428077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00428077.